title: My patient's diabetic kidney disease has progressed to stage 4; should I discontinue metformin?
authors.affiliation: Division of Endocrinology, Departments of Medicine and Community Health Sciences, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada. Electronic address: erik.venos@albertahealthservices.ca.
authors.forename: Erik S
authors.initials: ES
authors.lastname: Venos
authors.affiliation: Division of Endocrinology, Departments of Medicine and Community Health Sciences, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada; Department of Cardiac Sciences and Institute of Public Health, Faculties of Medicine and Kinesiology, University of Calgary, Calgary, Alberta, Canada.
authors.forename: Ronald J
authors.initials: RJ
authors.lastname: Sigal
mesh_terms: D000140:Acidosis, Lactic; D002170:Canada; D003928:Diabetic Nephropathies / Q000097:blood / Q000188:drug therapy*; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005919:Glomerular Filtration Rate; D006442:Glycated Hemoglobin / Q000187:drug effects; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D008687:Metformin / Q000008:administration & dosage*; D017410:Practice Guidelines as Topic
chemical_list: D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D008687:Metformin; C517652:hemoglobin A1c protein, human